NextGenNK
NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
NextGenNK and CCRM Nordic mini-symposium
On 22 January 2025, NextGenNK and CCRM Nordic are inviting you to a mini-symposium with the focus on ATMP.
Advanced Medicinal Therapy Products, ATMP, span broadly over medical fields and the aim of this symposium is to enhance networking within ATMP and to get a flavor of academic and commercial development of ATMPs in Stockholm and Sweden.
News
Awards and recognitions
Nutsa Burduli and Nicole Wild awarded Best Abstract at Collaboration in Science 2024
NextGenNK congratulates Nutsa Burduli and Nicole Wild on the Best Abstract awards.
NextGenNK at Innate Killer Summit 2023
co-leader Evren Alici was selected as one of the world-class speakers at Innate Killer Summit 2023.
Arnika Wagner - KID funding
Arnika Wagner, assistant professor at Karolinska Institutet, was granted KID funding for a new PhD student.
Anna Pumpe wins Best Poster Prize
NextGenNK congratulates Anna Pumpe (PhD student in Arnika Wagner’s team) who won “Best Poster Prize” at the KI-HERM retreat on 6 March 2024.
Selected Publications
Engineering immune-evasive allogeneic cellular immunotherapies
Martin KE et al, Nature Reviews Immunology, 2024.
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY et al, Science Translational Medicine 2024.
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity
Leijonhufvud C et al, The Journal of Immunology, 2024.